Skip to main content
TipRanks
Go Ultimate75% OFF

Spero Therapeutics (2HA) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

2HA Analyst Ratings

Moderate Buy
1Ratings
1Buy0Hold0Sell
Based on 1 analysts giving stock ratings to Spero Therapeutics in the past 3 months

2HA Stock 12 Month Forecast

€5.41▲(503.47% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Spero Therapeutics in the last 3 months. The average price target is EUR 5.41 with a high forecast of EUR 5.41 and a low forecast of EUR 5.41. The average price target represents a 503.47% change from the last price of EUR 0.90.
Highest Price Target€5.41Average Price Target€5.41Lowest Price Target€5.41

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:2HA
Price TargetArticle
Cantor Fitzgerald€5.41buy503.47%UpsideInitiated10/28/26
Evercore ISI€3.60hold302.31%UpsideReiterated12/17/25
TD Cowen―hold―Reiterated11/16/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
HROWHarrow Health
PLSEPulse Biosciences
DFTXDefinium Therapeutics
IMUXImmunic
MDWDMediwound

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Spero Therapeutics

3 Months
Kristen Kluska
Kristen KluskaCantor Fitzgerald
Success Rate0/1 ratings generated profit
0%
Average Return
-12.80%

Copying Kristen Kluska's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -12.80% per trade.

1 Year
Kristen Kluska
Kristen KluskaCantor Fitzgerald
Success Rate0/1 ratings generated profit
0%
Average Return
-12.80%

Copying Kristen Kluska's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -12.80% per trade.

2 Years
Kristen Kluska
Kristen KluskaCantor Fitzgerald
Success Rate0/1 ratings generated profit
0%
Average Return
-12.80%

Copying Kristen Kluska's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -12.80% per trade.

2HA Analyst Recommendation Trends

00.511.52Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for 2HA
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy00011
Buy00000
Hold00000
Sell00000
Strong Sell00000
total00011

In the current month, 2HA has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2HA average Analyst price target in the past 3 months is 5.41.

2HA Financial Forecast

€-2€-1.25€-0.5€0.25€1Q1 2026Q3 2026Q4 2026
High€-0.13
Consensus€-0.17
Low€-0.21

2HA Earnings Forecast

Next quarter’s earnings estimate for 2HA is -EUR 0.17 with a range of -EUR 0.21 to -EUR 0.13. The previous quarter’s EPS was -EUR 0.69. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€-1€9M€18M€27M€36MQ1 2026Q3 2026Q4 2026
High€0.00
Consensus€0.00
Low€0.00

2HA Sales Forecast

Next quarter’s sales forecast for 2HA is EUR 0 with a range of EUR 0 to EUR 0. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

2HA Stock Forecast FAQ

What is DE:2HA’s average 12-month price target, according to analysts?
Based on analyst ratings, Spero Therapeutics’s 12-month average price target is €5.41.
What is DE:2HA’s upside potential, based on the analysts’ average price target?
Spero Therapeutics has 503.47% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Spero Therapeutics a Buy, Sell or Hold?
Spero Therapeutics has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Spero Therapeutics’s share price target?
The average share price target for Spero Therapeutics is €5.41. This is based on 1 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €5.41, and the lowest forecast is €5.41. The average share price target represents a 503.47% increase from the current price of €0.896.
What do analysts say about Spero Therapeutics?
Spero Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Street analysts.
How can I buy shares of Spero Therapeutics?
To buy shares of DE:2HA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.